This clinical study consisted of three arms (A-C), with A. representing a dose-escalation arm of LY3200882 monotherapy in advanced solid tumors, B. a dose-expansion arm within grade 4 gliomas, and C. a combination treatment arm with LY3200882, a PD-L1 inhibitor LY3300054, cisplatin, and radiotherapy for a cohort of three patients with locoregionally advanced HNSCC. The gene discussed is CD274; the disease is head and neck squamous cell carcinoma.